source
- Boulevard Bio launches with $65 million to develop bispecific antibodies for IgA nephropathy and other autoimmune diseasesBoulevard Bio, a new biotech co-founded by autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle, announced its launch on Wednesday with $65 million in funding. The company’s first…
- Psychedelics developer Definium scores more positive data for LSD pillResults from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.BioPharma Dive · 47m ago↗ source